Another CBNs, Gd@C82(OH)22, a variant of metal-fullerol, has been tested as a nanodrug and showed to possess anti-pancreatic adenocarcinoma activity by exerting direct inhibition on the matrix metalloproteinases 9 (MMP-9), which ultimately restraining the proliferation of cancer cells19. This evidence concerns the gene MMP9 and pancreatic adenocarcinoma.